Role of paliperidone extended-release in treatment of schizoaffective disorder

QR Code

Role of paliperidone extended-release in treatment of schizoaffective disorder

Carla M Canuso1, Ibrahim Turkoz2, Dong Jing Fu3, Cynthia A Bossie31External Innovation Neuroscience Therapeutic Area, 2Biostatistics, Johnson &amp; Johnson Pharmaceutical Research and Development, LLC, Titusville, NJ, USA; 3CNS Medical Affairs, Ortho-McNeil Janssen Scientific Affairs, LLC, T...

Description complète

Enregistré dans:

Détails bibliographiques
Auteurs principaux:	Carla M Canuso, Ibrahim Turkoz, Dong Jing Fu, et al
Format:	article
Langue:	EN
Publié:	Dove Medical Press 2010
Sujets:	Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429
Accès en ligne:	https://doaj.org/article/adcc3cc9eec44cc5bcc3b18f4f62850a
Tags:	Ajouter un tag Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires

Direct and indirect effects of paliperidone extended-release tablets on negative symptoms of schizophrenia
par: Ibrahim Turkoz, et autres
Publié: (2008)

The role of paliperidone extended release for the treatment of bipolar disorder
par: Marino J, et autres
Publié: (2012)

The social functional outcome of being naturalistically treated with paliperidone extended-release in patients with schizophrenia
par: Nakagawa R, et autres
Publié: (2015)

Role of extended release quetiapine in the management of bipolar disorders
par: Rayan K Al Jurdi, et autres
Publié: (2010)

Combination therapy or monotherapy for the depressed type of schizoaffective disorder
par: Lubomira Iz&aacute;kov&aacute;, et autres
Publié: (2009)

An open-label, flexible-dose study of paliperidone extended-release in Chinese patients with first-onset psychosis
par: Si TM, et autres
Publié: (2015)

Paliperidone extended-release tablets in Chinese patients with schizophrenia: meta-analysis of randomized controlled trials
par: Cai SL, et autres
Publié: (2015)

Effects of paliperidone extended release on hostility among Thai patients with schizophrenia
par: Jariyavilas A, et autres
Publié: (2017)

An open-label, prospective study to evaluate social function and overall improvement of extended-release paliperidone treatment in Thai schizophrenia patients
par: Charnsil C, et autres
Publié: (2013)

Is schizoaffective disorder a distinct categorical diagnosis? A critical review of the literature
par: Daniel J Abrams, et autres
Publié: (2008)

Long-term tolerability of once-monthly injectable paliperidone palmitate in subjects with recently diagnosed schizophrenia
par: Sliwa JK, et autres
Publié: (2012)

Management of obsessive-compulsive disorder with fluvoxamine extended release
par: L&iacute;dia Ordacgi, et autres
Publié: (2009)

Comparative study of treatment continuation using second-generation antipsychotics in patients with schizophrenia or schizoaffective disorder
par: Azekawa T, et autres
Publié: (2011)

Update on extended release quetiapine fumarate in schizophrenia and bipolar disorders
par: El-Khalili N
Publié: (2012)

Interaction between paliperidone extended release and TS-1&reg;, an oral anticancer drug containing a 5-fluorouracil derivative, in a schizophrenic patient
par: Yasui-Furukori N, et autres
Publié: (2013)

Patients with schizophrenia or schizoaffective disorder who receive multiple electroconvulsive therapy sessions: characteristics, indications, and results
par: Iancu I, et autres
Publié: (2015)

Extended-release divalproex in bipolar and other psychiatric disorders: A comprehensive review
par: Steven C Stoner, et autres
Publié: (2007)

Profile of guanfacine extended release and its potential in the treatment of attention-deficit hyperactivity disorder
par: Martinez-Raga J, et autres
Publié: (2015)

Treatment satisfaction with paliperidone extended-release tablets: open-label study in schizophrenia patients dissatisfied with previous antipsychotic medication
par: Yang FD, et autres
Publié: (2017)

Improvement in social and cognitive functioning associated with paliperidone extended-release treatment in patients with schizophrenia: a 24-week, single arm, open-label study
par: Shi C, et autres
Publié: (2016)

Effects of once-daily extended release quetiapine fumarate on patient-reported outcomes in patients with generalized anxiety disorder
par: Endicott J, et autres
Publié: (2012)

The management of schizophrenia: focus on extended-release quetiapine fumarate
par: Peuskens J
Publié: (2011)

Once-monthly paliperidone injection for the treatment of schizophrenia
par: Delia Bishara
Publié: (2010)

Paliperidone ER: a review of the clinical trial data
par: Philip G Janicak, et autres
Publié: (2007)

Number needed to treat and number needed to harm with paliperidone palmitate relative to long-acting haloperidol, bromperidol, and fluphenazine decanoate for treatment of patients with schizophrenia
par: Srihari Gopal, et autres
Publié: (2011)

Efficacy, safety, and potential of extended-release lamotrigine in the treatment of epileptic patients
par: Barbara Błaszczyk, et autres
Publié: (2010)

Impact of extended-release dalfampridine on walking ability in patients with multiple sclerosis
par: Hayes KC
Publié: (2011)

Efficacy and safety of once-monthly injection of paliperidone palmitate in hospitalized Asian patients with acute exacerbated schizophrenia: an open-label, prospective, noncomparative study
par: Li HF, et autres
Publié: (2015)

Predictors of achieving remission in schizophrenia patients treated with paliperidone palmitate 3-month formulation
par: Nash AI, et autres
Publié: (2019)

Safety and tolerability of flexible dosages of prolonged-release OROS methylphenidate in adults with attention-deficit/hyperactivity disorder
par: Jan K Buitelaar, et autres
Publié: (2009)

Safety and efficacy of paliperidone extended-release in Chinese patients with schizophrenia: a 24-week, open-label extension of a randomized, double-blind, placebo-controlled study
par: Zhang H, et autres
Publié: (2016)

Dalfampridine extended release tablets: 1 year of postmarketing safety experience in the US
par: Jara M, et autres
Publié: (2013)

The safety and effectiveness of open-label extended-release carbamazepine in the treatment of children and adolescents with bipolar I disorder suffering from a manic or mixed episode
par: Findling RL, et autres
Publié: (2014)

Efficacy, safety, and impact on hospitalizations of paliperidone palmitate in recent-onset schizophrenia
par: Zhang F, et autres
Publié: (2015)

Longitudinal treatment responsiveness on plasma neurofilament light chain and glial fibrillary acidic protein levels in neuromyelitis optica spectrum disorder
par: Tian-Xiang Zhang, et autres
Publié: (2021)

Paliperidone palmitate and risperidone long-acting injectable in subjects with schizophrenia recently treated with oral risperidone or other oral antipsychotics
par: Alphs L, et autres
Publié: (2013)

Efficacy, tolerability, and safety of oral paliperidone extended release in the treatment of schizophrenia: a 24-week, open-label, prospective switch study in different settings in Taiwan
par: Chen CY, et autres
Publié: (2018)

Review of levetiracetam, with a focus on the extended release formulation, as adjuvant therapy in controlling partial-onset seizures
par: Carol M Ulloa, et autres
Publié: (2009)

Expansion of guidance for the day 8 initiation dose of paliperidone palmitate to avoid a missed dose
par: Samtani MN, et autres
Publié: (2013)

The cost reduction in hospitalization associated with paliperidone palmitate in the People’s Republic of China, Korea, and Malaysia
par: Chiou CF, et autres
Publié: (2015)